AN2 TherapeuticsANTX
13F holders, Q4 2025 (December 31)At the end of Q4 2025, 38 institutions reported holding AN2 Therapeutics Inc. (ANTX) in their 13F filings, up 2 from Q3 2025. 5 opened new positions and 3 sold out. The largest holders were Almitas Capital LLC ($1.7M), Vanguard Group Inc. ($1.2M) and Pfizer Inc ($815K). 3 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- AN2 Therapeutics Inc.
- CUSIP
- 037326105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $333K |
| Exits | 3 | $47K |
All 13F filers, Q3 2025 → Q4 2025: 547,689 shares bought and 159,431 shares sold, net +388,258 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 38 holders
| Almitas Capital LLC | 0.37% | Add +3.6% | 1,479,129 | $1.7M |
| Vanguard Group Inc. | 0.00% | No change | 1,080,070 | $1.2M |
| Pfizer Inc | 0.34% | No change | 715,295 | $815K |
| Stonepine Capital Management, LLC | 0.57% | Add +11.3% | 627,668 | $716K |
| Peapod Lane Capital LLC | 0.58% | Add +0.7% | 593,396 | $676K |
| Bank of Nova Scotia | 0.00% | No change | 459,194 | $523K |
| Landscape Capital Management, L.L.C. | 0.03% | Reduce -5.4% | 431,760 | $492K |
| Bank of Montreal | 0.00% | No change | 422,077 | $481K |
| Bank of America Corp. | 0.00% | Add +0.0% | 385,312 | $439K |
| Renaissance Technologies | 0.00% | Reduce -12.2% | 338,600 | $386K |
| BlackRock, Inc. | 0.00% | Add +0.8% | 323,335 | $369K |
| Two Sigma Advisers, LP | 0.00% | Reduce -1.1% | 264,900 | $302K |
| Geode Capital Management, LLC | 0.00% | Add +1.0% | 251,875 | $287K |
| Morgan Stanley | 0.00% | Add +20.4% | 229,770 | $262K |
| Two Sigma Investments, LP | 0.00% | Reduce -20.1% | 178,518 | $204K |
| Woodline Partners LP | 0.00% | New | 145,971 | $166K |
| Citadel Advisors | 0.00% | Add +402.1% | 115,536 | $132K |
| Millennium Management | 0.00% | New | 95,683 | $109K |
| State Street Corp. | 0.00% | No change | 87,002 | $99K |
| Rangeley Capital, LLC | 0.06% | No change | 65,000 | $74K |
| Squarepoint Ops LLC | 0.00% | Reduce -4.1% | 61,612 | $70K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 59,900 | $68K |
| UBS Group AG | 0.00% | Reduce -0.1% | 56,668 | $65K |
| Northern Trust Corp. | 0.00% | No change | 43,196 | $49K |
| Captrust Financial Advisors | 0.00% | No change | 40,000 | $46K |
| Private Advisor Group, LLC | 0.00% | No change | 22,500 | $26K |
| Susquehanna International Group, LLP | 0.00% | New | 22,240 | $25K |
| Jane Street Group, LLC | 0.00% | New | 17,935 | $20K |
| Schonfeld Strategic Advisors LLC | 0.00% | No change | 14,281 | $16K |
| Federated Hermes, Inc. | 0.00% | Reduce -3.4% | 11,479 | $13K |
| Valeo Financial Advisors, LLC | 0.00% | New | 10,446 | $12K |
| Qube Research & Technologies Ltd | 0.00% | No change | 10,184 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -4.1% | 2,040 | $2K |
| FMR LLC | 0.00% | Add +20.0% | 1,200 | $1K |
| Innovative Advisory Group, LLC | 0.00% | No change | 1,170 | $1K |
| BNP Paribas Financial Markets | 0.00% | No change | 303 | $345 |
| Osaic Holdings, Inc. | 0.00% | No change | 300 | $342 |
| SBI Securities Co., Ltd. | 0.00% | No change | 200 | $228 |
"% of holder's portfolio" is ANTX's weight in each manager's 13F, not the share of AN2 Therapeutics Inc. the manager owns.